Achillion Pharmaceuticals

Achillion is a science-driven, patient-focused company leveraging its strengths across the continuum from discovery to commercialization to provide better treatments for people with serious diseases. We use a highly-disciplined, scientifically rigorous, patient-focused approach across the continuum from discovery to patient care to discover and develop innovative medicines. Our prolific and sustainable discovery engine for potent and specific small-molecule drug candidates has produced breakthroughs for chronic hepatitis C (HCV) infection and a novel platform for the treatment of complement-mediated diseases. We have generated three clinical-stage, oral HCV candidates and a proprietary library of greater than 1,000 small molecule factor D inhibitors. Achillion is rapidly becoming a fully-integrated commercial pharmaceutical company as it advances the complement platform and prepares to bring life saving medicines to patients with rare diseases.
Company Growth (employees)
Type
Public
HQ
New Haven, US
Founded
1998
Size (employees)
81 (est)+3%
Achillion Pharmaceuticals was founded in 1998 and is headquartered in New Haven, US

Achillion Pharmaceuticals Office Locations

Achillion Pharmaceuticals has office in New Haven
New Haven, US

Achillion Pharmaceuticals Metrics

Achillion Pharmaceuticals Summary

Market capitalization

$531.8 m

Closing share price

$4
Achillion Pharmaceuticals's current market capitalization is $531.8 m.

Achillion Pharmaceuticals Financials

We estimate that Achillion Pharmaceuticals's revenue is $15 m in 2016
FY, 2013FY, 2014FY, 2015Y, 2016

Revenue

$66.1 m$15 m

Revenue growth, %

(77.3%)

Operating expense total

$59.5 m

EBIT

($59.5 m)($436.8 m)($441.9 m)

Net Income

($58.9 m)($436.8 m)($441.9 m)

Operating cash flow

$14.9 m

Achillion Pharmaceuticals Market Value History

We estimate that Achillion Pharmaceuticals's current employees are approximately 15% female and 85% male.

Achillion Pharmaceuticals Online Presence

Achillion Pharmaceuticals Company Life

You may also be interested in